At the same time, Duvelisib can reduce MCL-1 mRNA and expressed protein to a small extent, because MCL-1 can promote the survival of malignant lymphoma cells, which may increase the sensitivity of CLL cells to venetoclax[134. Here, MCL1 is linked to lymphoma.